982 related articles for article (PubMed ID: 33414052)
1. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
[TBL] [Abstract][Full Text] [Related]
2. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
3. A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid).
Sugimoto A; Matsumoto S; Udagawa H; Itotani R; Usui Y; Umemura S; Nishino K; Nakachi I; Kuyama S; Daga H; Hara S; Miyamoto S; Kato T; Sakakibara-Konishi J; Tabata E; Nakagawa T; Kawaguchi T; Sakai T; Shibata Y; Izumi H; Nosaki K; Zenke Y; Yoh K; Goto K
Clin Cancer Res; 2023 Apr; 29(8):1506-1514. PubMed ID: 36201167
[TBL] [Abstract][Full Text] [Related]
4. Clinical Utility of Cell-Free DNA for the Detection of
McCoach CE; Blakely CM; Banks KC; Levy B; Chue BM; Raymond VM; Le AT; Lee CE; Diaz J; Waqar SN; Purcell WT; Aisner DL; Davies KD; Lanman RB; Shaw AT; Doebele RC
Clin Cancer Res; 2018 Jun; 24(12):2758-2770. PubMed ID: 29599410
[No Abstract] [Full Text] [Related]
5. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
[TBL] [Abstract][Full Text] [Related]
6. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
7. Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.
Helman E; Nguyen M; Karlovich CA; Despain D; Choquette AK; Spira AI; Yu HA; Camidge DR; Harding TC; Lanman RB; Simmons AD
Clin Lung Cancer; 2018 Nov; 19(6):518-530.e7. PubMed ID: 30279111
[TBL] [Abstract][Full Text] [Related]
8. Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.
Mack PC; Banks KC; Espenschied CR; Burich RA; Zill OA; Lee CE; Riess JW; Mortimer SA; Talasaz A; Lanman RB; Gandara DR
Cancer; 2020 Jul; 126(14):3219-3228. PubMed ID: 32365229
[TBL] [Abstract][Full Text] [Related]
9. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
10. Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in situ hybridization.
Diks J; Tang Z; Altan M; Anderson S; Chen H; Rashid A; Yang RK; Routbort MJ; Patel KP; Toruner GA; Medeiros LJ; Tang G; Luthra R; Roy-Chowdhuri S
Cancer Cytopathol; 2024 Jan; 132(1):41-49. PubMed ID: 37747438
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of Genomic Alterations in Pericardial Effusion of Advanced Non-small Cell Lung Cancer.
He J; Hu X; Chen L; Liu Q; Jiang Y
Front Genet; 2022; 13():850290. PubMed ID: 35646096
[No Abstract] [Full Text] [Related]
12. One-Step Polymerase Chain Reaction-Free Nanowire-Based Plasma Cell-Free DNA Assay to Detect EML4-ALK Fusion and to Monitor Resistance in Lung Cancer.
Lee Y; Cho Y; Park EY; Park SY; Hwang KH; Han JY
Oncologist; 2021 Oct; 26(10):e1683-e1692. PubMed ID: 34272914
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea.
Ahn BC; Lee S; Lee J; Lee JB; Hong MH; Lim SM; Jain S; Olsen S; Cho BC
Cancer Treat Res Commun; 2023; 36():100715. PubMed ID: 37307681
[TBL] [Abstract][Full Text] [Related]
14. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer.
Palmero R; Taus A; Viteri S; Majem M; Carcereny E; Garde-Noguera J; Felip E; Nadal E; Malfettone A; Sampayo M; Riva F; Nagy RJ; Lanman RB; Faull I; Dix D; Karachaliou N; Rosell R
JCO Precis Oncol; 2021 Nov; 5():93-102. PubMed ID: 34994593
[TBL] [Abstract][Full Text] [Related]
15. Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers.
Hasegawa N; Kohsaka S; Kurokawa K; Shinno Y; Takeda Nakamura I; Ueno T; Kojima S; Kawazu M; Suehara Y; Ishijima M; Goto Y; Kojima Y; Yonemori K; Hayashi T; Saito T; Shukuya T; Takahashi F; Takahashi K; Mano H
Cancer Sci; 2021 Oct; 112(10):4393-4403. PubMed ID: 34310819
[TBL] [Abstract][Full Text] [Related]
16. Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
Tu HY; Li YS; Bai XY; Sun YL; Zheng MY; Ke EE; Liao RQ; Jiang BY; Lin JX; Huang J; Xu BF; Yang JJ; Zhang XC; Zhou Q; Wang BC; Chen HJ; Tong X; Yu R; Wu X; Zhu D; Wu YL
Clin Lung Cancer; 2022 Mar; 23(2):135-142. PubMed ID: 34645582
[TBL] [Abstract][Full Text] [Related]
17. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.
Li BT; Janku F; Jung B; Hou C; Madwani K; Alden R; Razavi P; Reis-Filho JS; Shen R; Isbell JM; Blocker AW; Eattock N; Gnerre S; Satya RV; Xu H; Zhao C; Hall MP; Hu Y; Sehnert AJ; Brown D; Ladanyi M; Rudin CM; Hunkapiller N; Feeney N; Mills GB; Paweletz CP; Janne PA; Solit DB; Riely GJ; Aravanis A; Oxnard GR
Ann Oncol; 2019 Apr; 30(4):597-603. PubMed ID: 30891595
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
Ghosh M; Mukhopadhyay M; Das C; Chatterjee S; Naskar BG
J Cancer Res Ther; 2021; 17(6):1389-1396. PubMed ID: 34916369
[TBL] [Abstract][Full Text] [Related]
19. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.
Dietz S; Christopoulos P; Yuan Z; Angeles AK; Gu L; Volckmar AL; Ogrodnik SJ; Janke F; Fratte CD; Zemojtel T; Schneider MA; Kazdal D; Endris V; Meister M; Muley T; Cecchin E; Reck M; Schlesner M; Thomas M; Stenzinger A; Sültmann H
EBioMedicine; 2020 Dec; 62():103103. PubMed ID: 33161228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
